Objective: Antipsychotic drug sensitivity in very late-onset schizophrenia-like psychosis (VLOSLP) is well documented, but poorly understood. This study aimed to investigate blood drug concentration, D2/3 receptor occupancy and outcome in VLOSLP during open amisulpride prescribing, and compare this with Alzheimer's disease (AD). Methods: Blood drug concentration, prolactin, symptoms and extrapyramidal side-effects (EPS) were serially assessed during dose titration. [ 18 F]fallypride imaging was used to quantify D2/3 receptor occupancy. Average steady-state amisulpride concentration (Caverage, ng/ml) was estimated by incorporating pharmacokinetic (PK) data into an existing population PK model (25 AD participants, 20 healthy older people). Results: Eight patients (target 20) were recruited (six women; 76 + À 6 years; six treatment compliant; five serially sampled; three with paired imaging data). Mean + À SD symptom reduction was 74 ± 12% (50-100 mg/day; 92.5 + À39.4 ng/ml). Mild EPS emerged at 96 ng/ml (in AD, severe EPS, 50 mg/day, 60 ng/ml). In three participants, imaged during optimal treatment (50 mg/day; 41-70 ng/ml), caudate occupancy was 44-59% (58-74% in AD across a comparable Caverage). Conclusions: Despite the small sample size, our findings are highly relevant as they suggest that, as in AD, 50 mg/day amisulpride is associated with >40% occupancy and clinically relevant responses in VLOSLP. It was not possible to fully characterise concentration-occupancy relationships in VLOSLP, and it is thus unclear whether the greater susceptibility of those with AD to emergent EPS was accounted for by increased central drug access. Further investigation of age-and diagnosis-specific threshold sensitivities is warranted, to guide amisulpride prescribing in older people, and therapeutic drug monitoring studies offer a potentially informative future approach.
Introduction
Older people with very late-(>60 years) onset schizophrenia-like psychosis (VLOSLP) (Howard et al., 2000) are amongst the most challenging mental health patient groups to engage and treat (Sin Fai Lam et al., 2016) . Typically presenting with systematised persecutory beliefs, they generally lack insight into their illness or the potential benefits of treatment (Howard et al., 1994) and are unwilling to engage with older adult mental health teams (Sin Fai Lam et al., 2016) . In those who initially accept antipsychotic drug treatment, heightened susceptibility to extrapyramidal side effects (Howard et al., 2000; Uchida et al., 2008) only increases the likelihood of noncompliance and subsequent disengagement from treatment and follow-up (Reeves et al., 2002; Hudson et al., 2004) .
The mechanisms underlying antipsychotic drug sensitivity in VLOSLP are poorly understood, as research in older people with schizophrenia rarely distinguishes between patients on the basis of age of illness onset (Jeste and Maglione, 2013; Uchida et al., 2008) , and the focus of research is increasingly directed towards those with dementia, who are at greatest risk of antipsychotic related morbidity and mortality (Jennum et al., 2015; Jeste et al., 2008; Maust et al., 2015; Howard et al., 2016) . Age-related changes in pharmacokinetics (PK), which reduce drug clearance, contribute to side effects by increasing blood drug concentration for a given dose (Feng et al., 2008; Uchida et al., 2009b) . However, this effect is not consistent across all antipsychotics (Bigos et al., 2008) and fails to account for the heightened sensitivity of people with dementia and VLOSLP to extrapyramidal side-effects (EPS) (Howard et al., 2000) compared to people with an earlier onset of schizophrenia.
The therapeutic window of striatal dopamine D2/3 receptor occupancy was first described for antipsychotic drugs (Farde et al., 1992; Kapur et al., 1995) , positron emission tomography (PET) has been used to guide safe and effective prescribing in young people (Uchida et al., 2011; Sparshatt et al., 2009; Lako et al., 2013) . In contrast, there is a relative paucity of imaging data in older clinical populations. Occupancy studies carried out in older patients with schizophrenia prescribed risperidone and/or olanzapine have consistently reported EPS at lower than anticipated threshold occupancies and have estimated that the optimal therapeutic window to avoid non-response and EPS is 50-60%, compared to 60-80% in young adults (Uchida et al., 2009a; Graff-Guerrero et al., 2015; Uchida et al., 2014) . These data suggest that age-related pharmacodynamic changes, which increase functional outcome for a given D2/3 receptor occupancy, contribute to antipsychotic drug sensitivity.
We have recently used an adapted [ 18 F]fallypride imaging protocol (Clark-Papasavas et al., 2014; Dunn et al., 2013) to investigate the relationship between dose, blood drug concentration and central D2/3 receptor occupancy in older patients with Alzheimer's disease (AD) and VLOSLP who were prescribed amisulpride off label to treat psychosis symptoms, as part of an open treatment study. Amisulpride dose-concentration , and concentration-occupancy profiles across a 25-75 mg/day dose range have been previously described in the AD group (Reeves et al., 2017) . Low amisulpride blood concentrations (9-109 ng/ml), which in all but one individual were below the recommended optimal therapeutic range (100-319 ng/ml) (Hiemke et al., 2011; Sparshatt et al., 2009) for the treatment of positive symptoms in schizophrenia, were associated with high D2/3 receptor occupancies (43-84% in the caudate), symptomatic improvement and emergent EPS, which ranged from mild to severe (Reeves et al., 2017) .
Our findings suggest that increased occupancy for a given blood drug concentration plays a key role in antipsychotic drug sensitivity in older people with AD, and implicate the blood brain barrier, which controls central drug access. However, the relative importance of the contribution of age and AD-specific changes to increased D2/3 receptor occupancy is unclear. The current study involves the analysis of data from VLOSLP participants in the study and aims to explore amisulpride doseconcentration-occupancy relationships and compare this with the situation in AD.
Methods

Sample
Patients with VLOSLP were recruited from the South London and Maudsley NHS Foundation Trust immediately prior to commencing amisulpride treatment. Participants were included on the basis of meeting diagnostic criteria for VLOSLP (Howard et al., 2000) , and having no previous history of psychotic illness (prior to 60 years), traumatic brain injury, epilepsy, significant cardiorespiratory disease, needle phobia, any contraindication to amisulpride or features suggestive of dementia. Patients were excluded if antipsychotic medication had been prescribed in the past 2 weeks (6 weeks if prescribed depot medication), or if unable to give informed consent. The study was approved by Berkshire Research Ethics Committee (REC reference 11/SC/0486).
Additional data sources. In order to control for variability in the timing of blood sampling, average steady-state concentration of amisulpride across the 24-h dosage interval was estimated by combining PK data from patients with VLOSLP with PK data from:
AD participants from the open study: 41 blood samples taken from 25 participants during steady-state amisulpride treatment with 25-75 mg/day (8 (32%) men; 82 + À6.6 years) .
A richly sampled phase I study carried out in healthy older people, each sampled 14 times over 72 h following a single oral 50-mg amisulpride dose (10 (50%) men; age = 68.7 ± 4.1 years) (HamonVilcot et al., 1998) . Venous blood samples (n = 280) were obtained from 20 healthy older participants. Amisulpride (racemate) concentrations were determined using a validated high performance liquid chromatography (HPLC) method (detection limit 0.5 ng/ml).
Baseline and follow-up assessments. Clinical assessments were carried out at baseline and every 14 ± 7 days during dose titration, and included (i) psychotic symptoms were rated using the summed total score of 3 items from the Brief Psychiatric Rating Scale (BPRS) which are most relevant for VLOSLP: unusual thought content, suspiciousness and hallucinations (Overall and Gorham, 1988) . Each item is scored on a 7 point scale, where 1 indicates 'symptom not present' and 7 'extremely severe' (ii) EPS were indexed as present or absence by scores of 3 or more on the clinician-rated Simpson-Angus Scale (SAS) (3-5 = mild; 6 or more = severe) (Simpson and Angus, 1970) and/or 2 or more on the Barnes Akathisia scale (Barnes, 1989) .
Amisulpride dose titration and blood sampling. Patients commenced amisulpride treatment at 50 mg/day and were followed up every 14 + À7 days, until an optimum dose was achieved (defined as >25% reduction in BPRS summed 3 item total scores). Compliance with medication (pill counts, discussion with a carer), concomitant medication and clinical outcome (symptom ratings, side effects) were recorded at each visit. Amisulpride venous blood concentration was measured prior to each dose increase, with the timing of blood samples coinciding with follow-up assessments and/or imaging. Blood samples were analysed in a secure, CPA accredited laboratory (Clinical Toxicology Unit, Kings College Hospital). Amisulpride (racemate) blood concentrations were determined using validated liquid chromatography with tandem mass spectrometry (LC-MS/MS) method, with a detection limit of 9 ng/ml. Prolactin concentration (PRL) was measured using chemiluminescence immune assay (Siemens Advia Centaur XP assay), with a detection limit of 6.4 mIU/L (0.29 ng/ml).
PET procedure. Participants were scanned on a GE (GE Healthcare, Hatfield, UK) VCT Discovery PET-CT camera (FWHM 5 mm), at St Thomas' Hospital PET Centre, using an interrupted [ 18 F]fallypride to achieve a transient equilibrium (Kegeles et al., 2008; Vernaleken et al., 2011) . [
18 F]fallypride binding potential BP ND (Innis et al., 2007) was quantified using a simplified reference tissue model with cerebellar reference region (Lammertsma and Hume, 1996) . Preprocessing was performed using statistical parametric mapping version 8 (www.fil.ion. ucl.ac.uk/spm) and all other analyses using Matlab (www.mathworks.com). Non-attenuation corrected, three-dimensional iteratively reconstructed PET scans (GE 'VuePoint') were used for frame-by-frame realignment. Transformations were applied to attenuation corrected, filtered back projected PET images which were used for quantification, and attenuation corrected-VuePoint PET images used for warping atlases. The cerebellum was defined using the Automated Anatomical Labelling atlas (TzourioMazoyer et al., 2002) and regions of interest (caudate, putamen, thalamus) were defined using the Tziortzi atlas (Tziortzi et al., 2011) . Atlases were warped to subject space via a [
18 F]fallypride template in standard space (Dunn et al., 2013) . Percentage reduction in BP ND between pre (BP PRE) and post (BP POST ) treatment scans was used to estimate occupancy, as follows: [(BP PRE À BP POST ) / BP PRE ] × 100.
Statistical analysis. Demographic and clinical data were described using SPSS (version 22.0) . Values are shown as mean ± SD. The original recruitment target was 20 patients, to allow direct comparison with AD patients and to control for age. Blood drug concentration is highly dependent on the timing of blood sampling, and, to control for this, average steady-state drug concentration across the dosage interval (Caverage) was estimated by incorporating PK data into a previously described, oral 2 compartment population PK model for amisulpride, developed from 25 AD and 20 healthy older participants ) (see additional data sources). The model described five parameters: (i) an absorption constant (ka); (ii) a central compartment (V1); (iii) a peripheral compartment (V2); (iv) an inter-compartmental distribution constant (Q); and (v) an elimination constant (CL), which includes renal and systemic clearance. Initial parameter estimates were based on previously described values and incorporated covariate effects (age and a scaling factor based on standard 70-kg body weight) on CL.
The population approach uses nonlinear mixed effect (NLME) modelling to examine doseconcentration relationships, identify sources of variability and make predictions for a typical person in the population of interest (Ette et al., 2004; Duffull et al., 2011) . Nonlinear mixed effect modelling, implemented using Monolix software (version 4.33; www.lixoft.eu), simultaneously estimates fixed effects (value for the average subject in the sample), and random effects (inter-individual variability, IIV) variance for parameters describing doseconcentration relationships and residual errors variance (unexplained variability, reflecting system noise, dosage history errors and/or model misspecifications). Inter-individual variability was estimated using an exponential model P i = P TV × e ηp where P i is the parameter estimate for the ith individual, and P TV is the typical value for the parameter at the population level. Random effects between ith individual and population parameter values (eta, η p ) were assumed to be normally distributed (mean of 0, variance ω η 2 ). As described previously , residual error was modelled separately for healthy older people and participants in the clinical study, to account for inter-study differences, and was described using a proportional residual error model (y ij = ŷ ij (1 + ε ij ), where y ij and ŷ ij represent the jth observed concentration of the ith subject and corresponding model-predicted concentration, and ε ij was assumed to be normally distributed (mean of 0, variance σ 2 )). The model was evaluated using goodness-of-fit criteria, including diagnostic scatter plots, visual predictive checks, degree of shrinkage model precision and likelihood ratio. Individual parameter estimates from the model included Caverage.
Results
VLOSLP sample characteristics
Eight patients (six women; age 76 ± 6 years) were recruited, two of whom were withdrawn due to lack of compliance with study procedures. Demographic and clinical data are presented in Table 1 . In six patients who complied with treatment, baseline BPRS 3 item total score was 18.3 + À 2.2 (6.5 + À 0.6 unusual thought content; 6.8 + À 0.4 suspiciousness; 5.0 + À 2.0 hallucinations). Following treatment with 50-100 mg/day amisulpride, there was a 74 ± 12% reduction in BPRS 3 item total scores (76 ± 15%, unusual thought content; 68% ± 20%, suspiciousness; and 69% ± 34%, hallucinations), with complete resolution of symptoms (BPRS score of 3) in two participants (Table 1) . Mild EPS, which did not lead to treatment discontinuation, emerged in two participants, and one was withdrawn from the study, after developing hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Pharmacokinetic, prolactin, imaging and clinical outcome data. Mean + À SD amisulpride blood concentration (n = 5) was 69.5 + À34.9 ng/ml; and corresponding PRL (5.6 + À1.5 pre-treatment), was 95 + À41 ng/ml (15 + À3 h post dose) after 21-191 days of treatment (PRL 88 + À72 ng/ml in AD). When PK data were incorporated into the existing PK model (Table 2) , parameter estimates were consistent with those previously described , and estimated Caverage was 92.5 + À39.4 ng/ml (range 41.5-129 ng/ml). Mild EPS (SAS score of 4) emerged at a lower threshold Caverage of 96 ng/ml (75 mg/day), and one participant developed akathisia (Barnes score of 3) at 129 ng/ml. In previously described AD participants, severe EPS (SAS scores of 11, 15 and 16) emerged at Caverage of 60, 61 and 62 ng/ml in three participants (Reeves et al., 2017) . Figure 1 shows Caverage, plotted against SAS scores for (a) AD and (b) VLOSLP groups, separated on the basis of mild (scores of 3-5) and severe (scores of 6 or above) EPS. Technical issues meant that it was only possible to carry out five pre-treatment scans (mean + À SD binding potential, BP PRE : 16.31 ± 1.32, caudate; 20.58 ± 2.0, putamen;1.49 ± 0.17, thalamus), and of five post-treatment scans attempted, only three produced data of sufficient quality due to technical issues (n = 1) or tolerability (n = 1) (mean + ÀSD binding potential, BP POST : 7.59 ± 1.56, caudate; 11.95 ± 3.94, putamen; 0.72 ± 0.25, thalamus) . Caverage and corresponding caudate occupancy in three participants who were imaged at an optimum 50 mg/day dose was 41 ng/ml (44%), 63 ng/ml (51%) and 70 ng/ml (59%). In AD, caudate occupancy ranged from 58 to 74% across Caverage 41-70 ng/ml. Caverage, plotted against caudate occupancy, is shown for VLOSLP and AD participants in Figure 2 .
Discussion
This study aimed to characterise amisulpride dose-PK-occupancy relationships in VLOSLP, using an adapted imaging protocol. Carrying out imaging studies in older people is highly challenging, particularly when combined with an active drug treatment, and participation requires a degree of insight and a level of engagement rarely achieved in people with VLOSLP (Howard et al., 1994; Sin Fai Lam et al., 2016) . As a consequence, recruitment and retention were poor, and, in addition, technical issues meant that it was only possible to obtain a complete dataset in three participants. Heightened sensitivity to EPS is well documented in VLOSLP (Howard et al., 2000; Uchida et al., 2008; Jeste and Maglione, 2013) , and open label trial data suggest that~100 mg/day (range 50-200 mg/day) amisulpride is efficacious in VLOSLP (Psarros et al., 2009 ), compared to older patients with an earlier illness onset, who tolerate doses up to 400 mg/day (Riedel et al., 2009) . Our findings were consistent with this, as clinically relevant responses were observed in VLOSLP patients at 50-100 mg/day, and correspondingly low blood drug concentrations. Small sample size meant that it was not possible to fully characterise the non-linear PK-occupancy curve in VLOSLP. However, our findings suggest that 50 mg/day amisulpride is associated with occupancies which achieve the therapeutic window (>40%) required to treat positive symptoms in young adults with schizophrenia (Sparshatt et al., 2009) . Occupancy data on low dose (50-100 mg/day) amisulpride treatment is highly variable in young adults, ranging from below 10% (Martinot et al., 1996; Xiberas et al., 2001 ) to 40% (la Fougere et al., 2005; Meisenzahl et al., 2008) in the striatum. This is partly accounted for by methodological differences (tracer, imaging modality, timing of the scan in relation to dose, scan duration) (Meisenzahl et al., 2008) but also reflects the steeper gradient of the occupancy slope at low blood drug concentrations (Vernaleken et al., 2004) . Our findings suggest that, as in AD, occupancies at least as high as those observed in young adults are observed in those with VLOSLP during treatment with 50 mg/day (Bressan et al., 2003; Lako et al., 2013; Sparshatt et al., 2009) .
As discussed previously (Reeves et al., 2017) , tracers with higher affinity (low dissociation constant) such as [18F]fallypride require higher concentrations of competing drug to displace them from receptor sites than those of lower affinity, leading to lower apparent occupancy (Seeman, 2011; Seeman, 2014; Seeman and Van Tol, 1995) . In vivo, this is particularly problematic if there is insufficient imaging time for the tracer to achieve equilibrium in the D2/3 rich striatum (Olsson and Farde, 2001; Xiberas et al., 2001; Vernaleken et al., 2011) . Although sampling times for the current study were guided by previous post-treatment [18F] fallypride protocols (Kegeles et al., 2008; Kessler et al., 2006) , we cannot rule out the possibility that we have under-estimated the true extent of the differences between young adults previously studied and those with AD and VLOSLP.
Previous imaging studies have estimated occupancy in risperidone and/or olanzapine treated older patients with schizophrenia, by comparing D2/3 receptor availability with a healthy older control group, and have estimated that occupancies of 60% or more are associated with EPS (compared to 80% in young adults) (Graff-Guerrero et al., 2015; Uchida et al., 2014) . These findings are not explained by differences in D2/3 receptor availability between 'antipsychotic free' patients and healthy older people (Nakajima et al., 2015) . In this respect, our findings are consistent with previous studies (EPS emerged around 60% occupancy) and supportive of a pharmacodynamic contribution to antipsychotic drug sensitivity in later life. However, the above studies differed in one important aspect, as they found that the relationship between blood drug (risperidone, olanzapine) concentration and occupancy in older patient was similar to that described in young adults.
It is possible that our finding of higher than anticipated occupancy in both AD and VLOSLP compared to previous studies may reflect the unique properties of amisulpride (lower lipophilicity, poor blood brain barrier (BBB) penetration relative to other antipsychotics) (Natesan et al., 2008) , which make the drug a more sensitive tool with which to explore BBB integrity. It will thus be important to use comparable methodology (drug, tracer, sampling times, method of analysis) in future studies. Other central mechanisms also need to be considered, as we cannot rule out the possibility that age and/or disease-specific changes in distribution and clearance of amisulpride within the central nervous system (Uchida et al., 2009b) , and/or reduced competition due to lower endogenous dopamine levels (Volkow et al., 1994) in those of extreme age contributed to our findings.
Although there appears to be some overlap between AD and VLOSLP, at least in terms of minimum clinically effective dose, there are also clear differences in sensitivity to side effects, as severe EPS emerged in AD during treatment with 50 mg/day, and at very low threshold drug concentrations (60 ng/ml). Differences between the two groups were not accounted for by variability in the timing of blood samples, as the PK model allowed estimation of average concentration across the dosage interval for each individual, accounting for the impact of age and body weight. It is tempting to speculate that the exquisite sensitivity in AD is explained by higher occupancy for a given for a given amisulpride blood concentration, due to greater disruption in BBB integrity (Zeevi et al., 2010) . However, given the very small sample size, it is equally possible that other confounding factors, such as age, gender or concomitant medication, explain differences in tolerability.
Non-adherence is a potential source of error when attempting to estimate dose-PK-response relationships. Although compliance was facilitated and closely monitored, tablet counts and self-report are not wholly reliable (Blaschke et al., 2012) and may have contributed to IIV in parameter estimates and residual error. The issue of diagnosis is important when psychosis is present in the context of a dementia, and careful screening was thus carried out to exclude patients with suspected Lewy Body Dementia, included dopamine transporter imaging where appropriate (McKeith et al., 1996) . While we cannot completely rule out the possibility that Lewy body pathology may have contributed to the observed drug sensitivity in AD, EPS are sufficiently explained by higher than anticipated occupancies which exceeded the 60% threshold.
Conclusion
Despite the limitations of the clinical dataset, this dataset is important, as it suggests that target amisulpride concentrations to treat psychosis in AD and VLOSLP overlap and are lower than the currently recommended target range (100-320 ng/ml) (Sparshatt et al., 2009) , due to higher than anticipated central D2/3 receptor occupancies. Our preliminary findings also argue strongly for further investigation of disease-specific differences in antipsychotic drug sensitivity, as the target therapeutic amisulpride concentration range appears to be broader in VLOSLP, overlapping both with AD and schizophrenia of an earlier onset. Whether this is due to differences in the PK-occupancy slope is unclear, given the sample size limitations. In young adults, it has been shown that amisulpride blood concentration is a more sensitive predictor of EPS than D2/3 receptor occupancy (Sparshatt et al., 2009) . Given the challenges faced when attempting occupancy studies in older people, large-scale amisulpride therapeutic drug monitoring studies offer a more feasible, cost-effective alternative approach to future research, and one which will directly inform age-and disease-specific dose adjustments. Alongside this, research needs to be directed towards improving service engagement in people with VLOSLP.
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Key points
• The study aimed to investigate amisulpride dose, concentration (Caverage), D2/3 receptor occupancy and outcome in VLOSLP and compare this with Alzheimer's disease (AD).
• Clinically relevant responses were observed at 50-100 mg/day, Caverage 41-129 ng/ml, with mild EPS emerging at 96 ng/ml (Severe EPS emerged at 60 ng/ml in AD).
• Caudate occupancy was 44-59% in three VLOSLP participants imaged at Caverage 41-70 ng/ml (58-74% in AD, across the same Caverage range).
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